TSPARXA
Live / Registered — Registered (as of 18 Jan 2022)
What this means for you
Registered since 18 Jan 2022. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 18 Jan 2028: the §71 affidavit of use).
Record
- Serial number
- 79317249
- Registration number
- 6617412
- Mark type
- Word mark
- Filed
- 18 Jun 2021
- Published for opposition
- 02 Nov 2021
- Registered
- 18 Jan 2022
- Next maintenance filing
- §71 affidavit of use, due by 18 Jan 2028 (grace period to 18 Jul 2028)
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of cancer
Owner
- Sumitomo Pharma Co., Ltd., Osaka 541-0045, JP
- Sumitomo Dainippon Pharma Co., Ltd., JP
- Sumitomo Dainippon Pharma Co., Ltd., JP
- Sumitomo Dainippon Pharma Co., Ltd., JP
Prosecution history
- 08 Nov 2022 — CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
- 04 Nov 2022 — CHANGE OF NAME/ADDRESS REC'D FROM IB
- 23 Sept 2022 — NEW REPRESENTATIVE AT IB RECEIVED
- 21 Aug 2022 — CORRECTION TRANSACTION RECEIVED FROM IB
- 05 Jun 2022 — NOTIFICATION PROCESSED BY IB
- 16 May 2022 — FINAL DISPOSITION NOTICE SENT TO IB
- 16 May 2022 — FINAL DISPOSITION PROCESSED
- 17 Mar 2022 — CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
- 17 Feb 2022 — GRANT OF PROTECTION CREATED, TO BE SENT TO IB
- 18 Jan 2022 — REGISTERED-PRINCIPAL REGISTER
- 14 Jan 2022 — CORRECTION TRANSACTION RECEIVED FROM IB
- 02 Nov 2021 — PUBLISHED FOR OPPOSITION
- 13 Oct 2021 — NOTICE OF PUBLICATION
- 23 Sept 2021 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 23 Sept 2021 — ASSIGNED TO EXAMINER